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Abstract 
 
Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 
of β2glycoproteinI in terms of risk of thrombosis and pregnancy complications in patients with 
antiphospholipid syndrome. To obtain direct evidence for the pathogenic role of anti-domain 1 or 
anti-domain 4/5 antibodies, we analysed the in vivo pro-coagulant effect of two groups of 5 serum 
IgG each reacting selectively with domain 1 or domain 5 in LPS-treated rats. Antibody-induced 
thrombus formation in mesenteric vessels was followed by intravital microscopy and vascular 
deposition of β2glycoproteinI, human IgG and C3 was analyzed by immunofluorescence. Five 
serum IgG with undetectable anti-β2glycoproteinI antibodies served as controls. All the anti-domain 
1 positive IgG exhibited potent pro-coagulant activity while the anti-domain 5 positive and the 
negative control IgG failed to promote blood clot and vessels occlusion. A stronger granular deposit 
of IgG/C3 was found on the mesenteric endothelium of rats treated with anti-domain 1 antibodies, 
as opposed to a mild linear IgG staining and absence of C3 observed in rats receiving anti-domain 5 
antibodies. Purified anti-domain 5 IgG, unlike anti-domain 1 IgG, did not recognize cardiolipin-
bound β2glycoproteinI while able to interact with fluid-phase β2glycoproteinI. These findings may 
explain the failure of anti-domain 5 antibodies to exhibit in vivo thrombogenic effect and the 
interaction of these antibodies with circulating β2glycoproteinI suggest their potential competitive 
role with the pro-coagulant activity of anti-domain 1 antibodies. These data aim at better defining 
“really at risk” patients for more appropriate treatments to avoid recurrences and disability. 
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Introduction  
 
Antiphospholipid syndrome (APS) is a chronic autoimmune disorder characterized by recurrent 
episodes of vascular thrombosis and adverse pregnancy outcomes in the presence of antibodies to 
phospholipid-binding proteins (aPL) and occurs either as a primary disease or concomitantly to 
other connective tissue diseases, particularly systemic lupus erythematosus.1 Although thrombotic 
occlusion may affect the vessels of all organs and tissues, deep vein thrombosis in the legs often 
complicated by pulmonary embolism, and thrombotic occlusion of cerebral and coronary arteries 
leading to stroke and myocardial infarction respectively are common presentations of the 
syndrome.2 This clinical condition is also associated with pregnancy morbidity including fetal loss, 
pre-eclampsia, pre-term delivery and small for gestational age babies.3 These are serious 
complications that affect particularly young people and have both social and economic impacts. The 
disease may sometimes present as catastrophic syndrome, a more severe form of APS characterized 
by microthrombosis of small vessels in various organs resulting in multiple organ failure.4 
Anti-cardiolipin (aCL) and anti-β2glycoprotein I (β2GPI) antibodies and lupus anticoagulant (LA) 
activity are considered markers of APS and are included among the criteria currently proposed for 
the classification of this syndrome.1 
Clinical studies have revealed an increased risk of thrombosis and pregnancy complications in 
patients with medium to high levels of these antibodies and LA present in their plasma.5 The triple 
positivity of these laboratory markers has also been shown to be associated with more severe forms 
of APS.5 Conversely, the positivity for a single marker is often associated with a much lower risk 
for the APS clinical manifestations.5-9 
It has been widely demonstrated that β2GPI is the main antigen recognized by aPL and the 
reactivity against the protein has been shown to be responsible for the positivity for aCL and anti-
β2GPI assays and in part for the LA phenomenon strongly associated with the APS clinical 
manifestations.10 
β2GPI circulates in blood mainly in a circular form and is organized into four domains (D1-4) 
composed of 60 amino acids with two disulfide bonds and a fifth domain (D5) containing extra 24 
amino acids that interacts with anionic phospholipids on the target cells/tissues.11 Besides the 
classical diagnostic assays measuring antibodies against whole molecule β2GPI, new  tests have 
recently been developed to detect anti-β2GPI antibody subpopulations reacting with different 
domains of the protein, particularly the combined domains D4/5 and Domain 1 (D1).5-7,9,12-14 
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In APS patients a large proportion of anti-β2GPI antibodies reacts with D1 and recognizes a criptic 
epitope (Arg39–Arg43) in the native molecule exposed following its interaction with anionic 
phospholipids 13,15 or oxidation.16-18 Antibodies directed against D1 of β2GPI with or without anti-
D4/5 antibodies have frequently been found in APS patients associated with an increased risk of 
thrombosis and pregnancy complications.7,9,19-24 By contrast, isolated high levels of anti-D4/5 
antibodies have been reported in non-APS patients with leprosy, atopic dermatitis, atherosclerosis 
and in children born to mothers with systemic autoimmune diseases 6 and in asymptomatic aPL 
carriers and are not associated with either vascular or obstetric manifestations of the APS 
syndrome.7,9  This finding prompted some authors to suggest that the ratio between anti-D1 and 
anti-D4/5 may be a useful parameter for identifying autoimmune APS and for ranking the patients 
according to their risk to develop the syndrome.7 
An isolated positivity for anti-D4/5 is a rare condition, which is usually associated with the absence 
of aCL and/or LA and in the majority of the cases with doubtful APS picture which does not fulfill 
the classification/diagnostic criteria.25 The finding that antibodies with this isolated specificity are 
observed mainly in the absence of clinical manifestations of hypercoagulable states has suggested 
that they may not be involved in thrombus formation.  
While the in vivo pathogenic role of aPL has been demonstrated for those directed against the whole 
molecule and against D1 of β2GPI using animal models of thrombosis developed in rats and mice, 
26-28
 direct evidence that antibodies to D4/5 do not play an in vivo pathogenic role in blood clotting 
is presently lacking nor is it clear whether they are able to interact with soluble or surface bound 
β2GPI. Data will be presented indicating that the antibodies are ineffective in causing blood clot due 
to their failure to recognize bound β2GPI. 
 
Methods 
 
Serum source 
Two groups of anti-β2GPI positive sera7,27 containing isolated antibodies to either D1 or D4/5 
domains6,7 and control sera with undetectable anti-β2GPI antibodies were analysed. All samples 
were also tested for aCL antibodies7 and LA activity.29 The anti-D1 positive sera were obtained 
from APS patients.1 The sera were collected after obtaining informed consent and the IgG were 
purified by a Protein G column (HiTrap Protein G HP, GE Healthcare) as described.27 The 
local Istituto Auxologico Italiano ethical committee approved the study. 
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Purification of β2GPI and generation of recombinant domains D4 and D5 
The purification of human β2GPI from pooled normal sera27,30 and the generation of D4 and D5 
domains12,31 have been published. Sequence analysis was performed as described32 and 
compared to the published sequence of β2GPI.33 The fine specificity against D4 or D5 was 
investigated by ELISA.27 
 
Animal model 
An in vivo model of antibody-induced thrombus formation was established in male Wistar rats 
(270-300g) and kept under standard conditions in the Animal House of the University of 
Trieste, Italy as previously reported in details.26 The in vivo procedures were performed in 
compliance with the guidelines of European (86/609/EEC) and Italian (D.L.116/92) laws and 
were approved by the Italian Ministry of University and Research and the Administration of 
the University Animal House. This study was conducted in accordance with the Declaration of 
Helsinki. Details reported in the Supplementary Methods. 
 
Immunofluorescence analysis 
The mesenteric tissue was collected from rats at the end of the in vivo experiment.26 Deposits 
of β2GPI were analyzed using the biotinylated monoclonal antibody MBB2 and FITC-labeled 
streptavidin (Sigma-Aldrich).27 IgG and C3 were detected using FITC-labeled goat anti-human 
IgG (Sigma-Aldrich) and goat anti-rat C3 (Cappel/MP Biomedicals) followed by FITC-labeled 
rabbit anti-goat IgG (Dako), respectively. The slides were examined using a DM2000 
fluorescence microscope equipped with DFC 490 photo camera and the Application Suite 
software (Leica). 
 
Antibody binding assays 
Different concentrations of β2GPI were added to CL-coated plates and the reactivity of IgG 
with CL-bound β2GPI was measured.7 The interaction of IgG with soluble β2GPI was evaluated 
by incubating IgG with increasing concentrations of β2GPI or BSA as unrelated antigen for 1 
hour at 37°C followed by overnight incubation at 4°C in a rotator. The samples were 
centrifuged at 3,000 g for 5 min at room temperature and the residual un-complexed antibodies 
were tested using β2GPI-coated plates (Combiplate EB, Labsystems) as described.7 Details 
reported in the Supplementary Methods. 
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Statistical analysis 
Statistical analysis was performed using GraphPad Prism 6.0 for Windows. The domain 
reactivity of the anti-β2GPI D4/5 positive sera was expressed as mean+SD and analyzed with 
the paired Student’s t test. Data from in vivo thrombus formation were compared by Dunnett’s 
test. The interaction between IgG and β2GPI bound to CL was analyzed with the Kruskall-
Wallis with Dunn’s post-hoc test. The interaction between IgG and soluble β2GPI was 
expressed as median and interquartile range and analyzed with the 2way repeated measure 
ANOVA with Sidak’s post-hoc test. Probabilities of <0.05 were considered statistically 
significant. 
 
Results 
 
aPL profile of the serum samples  
Anti-β2GPI IgG titers were comparable in the anti-D4/5 and anti-D1 positive samples (1.04 + 0.26 
OD and 1.46 + 0.48 OD, mean + SD, respectively). The isolated anti-D4/5 positive samples 
displayed anti-D4/5 level of 50.67+ 9.86 AU (mean + SD) while they were negative for aCL (<10 
GPL) and LA. The isolated anti-D1 positive samples showed anti-D1 level of 75.36 + 17.15 AU 
(mean + SD), high titers of IgG aCL (124.4 + 46.9 GPL, mean + SD) and displayed LA activity.  
Control samples were negative in all the assays. The purified IgG fractions  maintained the antigen 
specificity shown in the whole serum. Clinical and serological data of all the included 
subjects/patients are reported in Supplementary Table 1. 
 
Fine epitope-specificity of antibodies to D4/5 
The IgG against D4/5 used in this study were selected for their ability to react with the combined 
domains obtained from INOVA Diagnostics, but it was unclear whether they recognized one or the 
other domain or both. To clarify this point, we assessed the reactivity of serum IgG towards 
recombinant D4 and D5 domains. The amino acid sequences of the two domains are reported in 
Supplementary Figure 1. The results presented in Figure 1 clearly show that all the anti-D4/5 
reacted with D5 and did not recognize D4. The difference in the reactivity of the various serum IgG 
towards D4/5 is essentially similar to that observed in their reaction with D5. 
 
Antibodies to D5 fail to cause thrombus formation in vivo 
To evaluate the pro-coagulant activity of sera containing antibodies to different domains of β2GPI, 
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two groups of serum IgG positive for either D1 or D5 domains were analyzed for their ability to 
induce thrombus formation followed in vivo by intravital microscopy. IgG from sera negative for 
antibodies to β2GPI served as a control group. As shown in Figure 2, all anti-D1 positive IgG 
induced blood clots that started to be seen 15 min after serum infusion. Their number progressively 
increased to reach the highest value after 1 hour and was maintained thereafter up to 90 min. 
Thrombus formation was associated with vascular occlusion that resulted in marked decrease, and, 
in some vessels, in complete blockage of blood flow. Conversely, the anti-D5 positive IgG did not 
exhibit pro-coagulant activity and failed to cause reduced blood flow. The latter results were not 
statistically different from those of anti-β2GPI negative blood donors at each time point. On the 
contrary, the data of anti-D1 IgG were statistically different from those of anti-β2GPI negative 
samples at all times starting from 15 minutes of analysis with a P <0.05. 
 
Antibodies to D5 fail to interact with surface-bound β2GPI 
Having observed absence of intravascular coagulation in rats that had received anti-D5 positive 
IgG, we decided to investigate whether this was due to the inability of the antibodies to interact with 
endothelium-bound β2GPI. To this end, samples of ileal mesentery were analyzed for the presence 
of β2GPI, human IgG and C3. As expected from our previous findings,30 β2GPI was detected on the 
vessel endothelium of rats primed with LPS (Figure 3), while totally absent in unprimed animals 
(data not shown). Search for IgG and C3 revealed marked granular deposits of both proteins on 
endothelial cells of rats treated with anti-D1 IgG, while a milder linear staining for IgG and absence 
of C3 were observed in rats receiving anti-D5 IgG (Figure 3). The animals treated with anti-β2GPI 
negative sera showed negligible staining for IgG and undetectable C3 (Figure 3). Since several 
molecules other than β2GPI are expressed on the endothelial cell surface and represent potential 
targets for human IgG, we set out to determine whether the fluorescence was due to the IgG 
specifically against β2GPI. To do this, we set up a β2GPI-dependent CL assay in which the β2GPI 
supplementation was carried out by adding human purified β2GPI at increasing concentrations 
instead of fetal calf serum. The system allowed us to test the IgG reactivity with β2GPI added at 
different concentrations to the CL-plates. As shown in Figure 4, the anti-D1 IgG reacted with the 
β2GPI molecule most likely by recognizing the D1 epitope exposed on the β2GPI molecule 
following its binding to cardiolipin. The IgG level detected in the assay varied in different patients 
and was related to the concentration of β2GPI used to coat cardiolipin. In contrast, anti-D5 IgG 
failed to interact with cardiolipin-bound β2GPI even at the highest concentration of β2GPI, 
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suggesting that D5 domains were not accessible to the antibodies under these experimental 
conditions. Like the anti-D5 antibodies, the IgG from control sera were negative in the assay. 
 
Antibodies to D5 interact with soluble β2GPI 
Electron microscopy studies have revealed that β2GPI adopts a circular form in plasma maintained 
by the interaction of D1 with D5.34 This special conformation prevents the access of autoantibodies 
to hidden epitopes on D119 and predicts the presence of cryptic epitopes on D5, though this has not 
been formally proven.35 
We first decided to examine the in vivo interaction of the antibodies with circulating β2GPI and the 
effect of this interaction on β2GPI bound to vascular endothelium. To this purpose, the in vivo 
model was slightly modified administering IgG intraperitoneally followed 15 hours later by LPS 
given by the same route. This approach would allow sufficient time to the antibodies to react with 
the target antigen prior to the binding of β2GPI to vascular endothelium promoted by LPS. The IgG 
from two sera with relatively high levels of antibodies to D1 and D5 respectively, and from an anti-
β2GPI negative serum were tested and the amount of vascular deposits of β2GPI and IgG was 
evaluated. As expected, the rat treated with anti-D1 developed endovascular thrombi associated 
with deposition of IgG, both of which were undetectable in animals that received anti-D5 positive 
or anti-β2GPI negative IgG (Figure 5). Analysis of the ileal mesentery showed that β2GPI was 
present on the vascular endothelium of the animals that received the three IgG fractions with no 
clear difference in the staining intensity observed in the rats treated with anti-D5 and anti-D1 IgG 
(Figure 5). 
Since the in vivo data did not provide convincing evidence on the ability of anti-D5 to prevent 
binding of circulating β2GPI to vascular endothelium, we decided to further investigate this issue 
using an in vitro inhibition assay. IgG purified from anti-D5 positive, anti-D1 positive or anti-β2GPI 
negative sera were incubated with increasing concentrations of soluble β2GPI and the residual IgG 
interacting with β2GPI directly bound to the plate wells were measured. As shown in Figure 6, the 
amount of IgG anti-D5 free to bind to solid-phase β2GPI after incubation with the soluble molecule 
decreased compared to that of the IgG incubated with BSA, particularly at higher concentration of 
soluble β2GPI. In contrast, the level of IgG anti-D1 bound to solid-phase β2GPI following 
incubation with soluble β2GPI was slightly lower, but not significantly different from that of the 
IgG incubated with BSA. 
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Discussion 
 
APS is now recognized as an antibody-dependent and complement-mediated syndrome and 
antibodies to β2GPI have been identified as important players in thrombus formation in APS 
patients.10 Efforts are being made to determine the clinical relevance of antibodies to D1 and D4/5 
domains of the molecule detected in these patients. Clinical studies have suggested that antibodies 
to D4/5, unlike those directed against D1, do not represent a risk factor for thrombosis and 
pregnancy complications.7,9,14 The in vivo data presented here focused on the thrombotic aspect of 
the syndrome and support the clinical observation that the anti-D4/5 antibodies are pathologically 
irrelevant.  
The animal model used in this and in previous studies proved to be an invaluable tool to investigate 
the ability of the anti-β2GPI antibodies to induce blood clots in rats primed with LPS that provides 
the first hit followed by the infusion of the antibodies acting as a second hit.10 As expected, all anti-
D1 IgG promoted thrombus formation and vascular occlusion confirming the pathogenicity of these 
antibodies suggested by the clinical observations. It is possible that LA detected in the plasma of 
these patients may have also contributed to anti-β2GPI-induced blood clots. However, although 
β2GPI antibody-dependent LA has been shown to correlate with the increased risk of thrombosis, 
13,14,36
 evidence supporting the in vivo pro-thrombotic activity of LA independent of anti-β2GPI 
antibody has not been provided yet. Instead, there is good evidence that the antibodies recognizing 
the D1 domain of β2GPI are directly involved in thrombus formation and vessel occlusion. We have 
previously shown that a human monoclonal antibody that recognizes D1 induces blood clots and 
that a CH2-deleted non-complement fixing variant molecule competes with anti-β2GPI antibodies 
from APS patients and prevents their pro-coagulant activity.27 A similar inhibitory effect was 
obtained using recombinant D1 to control the thrombus enhancement activity of aPL in mice.37 
The in vivo experiments showed that none of the anti-D5 IgG exhibited a prothrombotic activity 
supporting the observations made in clinical studies that these antibodies are pathologically 
irrelevant.7,14 A possible explanation for this finding is the inability of these antibodies to interact 
with cell-bound β2GPI. In line with this hypothesis we showed that anti-D5 positive IgG fractions 
were unable to react with β2GPI bound to CL-coated plates in vitro because of the shielding of D5 
in the β2GPI molecule bound to CL-coated plate. However, the mild staining for IgG on the 
endothelium of mesenteric vessels observed in vivo in rats treated with LPS, to promote binding of 
β2GPI, and anti-D5 IgG did not allow any definite conclusion on this issue. It must be emphasized, 
however, that the staining intensity varied among different sera and was not related to the level of 
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antibodies. The linear deposition of IgG on the mesenteric endothelium from rats treated with anti-
D5 positive IgG suggests their interaction with antigens constitutively expressed on endothelial 
cells. This distribution pattern differs from the irregular staining for IgG seen with the anti-D1 
positive IgG most likely explained by their reaction with a plasma derived molecule, such as β2GPI, 
bound to the endothelial cell surface. The different distribution of anti-D1 and anti-D5 IgG 
resembles the well-known difference in the granular and linear distribution patterns of IgG observed 
in the kidney of patients with Systemic Lupus Erythematosus (SLE) and Good-Pasture respectively. 
The linear pattern of IgG in Good-Pasture is the result of interaction of the antibodies with their 
target antigen constitutively expressed on the glomerular basement membrane. In contrast, the 
granular distribution of IgG in SLE is caused by irregular deposition of circulating immune 
complexes.38,39 The finding that C3 deposition was undetectable on the vascular endothelium of rats 
treated with anti-D5 IgG is consistent with the failure of these antibodies to induce thrombus 
formation. We and others have provided convincing evidence that complement activation is 
critically involved in the coagulation process induced by anti-β2GPI IgG and in this study by 
antibodies to the D1 domain.26,27,40-43 
The anti-D4/D5 antibodies present in the sera analysed in this study recognized selectively the 
recombinant D5 domain and are likely to inhibit deposition of β2GPI on the endothelium by 
shielding its binding site for the anionic phospholipid on endothelial cells.44  Our attempt to 
document ex vivo reduced binding of circulating β2GPI to vascular endothelium of the anti-D5-
treated rats was unsatisfactory most likely due to an exceedingly higher level of serum β2GPI 
compared to that of injected antibodies in vivo. The in vitro data obtained under more controlled 
conditions of IgG and β2GPI concentrations showed a fluid phase interaction between anti-D5 IgG 
and soluble β2GPI, resulting in a significantly reduced reactivity of these antibodies against surface-
bound β2GPI (when the molecule was bound to a plate). 
The finding that anti-D5 IgG have no pro-coagulant effect in our in vivo model has important 
clinical implications suggesting that individuals with isolated presence of these antibodies should 
not be considered at risk of thrombosis. It should be pointed out, however, that anti-D1 and anti-D5 
IgG often co-exist in a large proportion of APS patients, who are likely to be susceptible to anti-D1-
dependent thrombus formation. In view of the ability of the anti-D5 IgG to interact with soluble 
β2GPI preventing its binding to the target cells, it is tempting to speculate that the anti-D5 IgG may 
antagonize the pro-coagulant activity of anti-D1 antibodies, depending on the antibody levels. 
Accordingly, we recently published data indicating that the risk of thrombosis in patients positive 
for anti-D1 and anti-D4/5 antibodies is reduced if the levels of anti-D4/5 are higher than those of 
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anti-D1 antibodies.7,9 Overall our experimental findings fit with the clinical observation, offering 
new tools for stratifying patients into different risk categories. This would help in better preventing 
recurrences of the clinical manifestations and avoiding overtreatment, so ultimately improving the 
patients’ quality of life and sparing side effects of treatment. 
In conclusion, the data presented in this work indicate that, unlike the anti-D1 positive sera, those 
containing antibodies against D5 are unable to induce clot formation and vascular occlusion. The 
failure of the anti-D5 antibodies to promote coagulation is due mainly to their inability to interact 
with the target epitopes hidden on the surface-bound molecule and possibly to the recognition of 
native β2GPI in plasma that may potentially prevent to some extent its binding to the surface of 
activated endothelial cells. The detection of anti-D5 antibodies in patients with doubtful clinical 
picture and a single positivity for anti-β2GPI in the absence of a positive aCL assay may offer a 
valuable tool for ruling out a definite APS diagnosis and for identifying subjects at lower risk for 
clinical manifestations. 
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Figure legends. 
Figure 1. Anti-domain (D) 4/5 antibodies specifically react against domain (D) 5 of 
β2glycoprotein I (β2GPI). Reactivity of 5 anti-D4/5 positive patient sera (P1-P5) against different 
recombinant human β2GPI domains: (A) reactivity against the combined D4/5 peptides (    ), in an 
assay produced for research use (QUANTA Lite β2GPI D4/5 ELISA, INOVA Diagnostics) (B) 
reactivity against the recombinant domains D4 (     ) or D5 (      ) antigens separately immobilized 
on the wells of γ-irradiated polystyrene plates in an in-house ELISA plates. The OD values are 
expressed as mean ± SD. The data were analyzed with the Student’s t test for paired data. The 
average reactivity against D5 is significantly higher than that against D4 (P = 0.0428). 
 
Figure 2. Anti-domain (D) 5 antibodies fail to induce thrombi in rats. Thrombus formation and 
vascular occlusion visualized by intravital microscopy in the ileal mesentery of rats that received an 
intraperitoneal injection of LPS (2.5 mg/kg body weight) followed by the injection into carotid 
artery of antibodies (10 mg/rat) directed against domain 5 (D5), domain 1 (D1), or anti-
β2glycoprotein I (β2GPI) negative (NHS). The number of thrombi (A) and vessel occlusions (B) 
were evaluated at various time intervals on 3 rats per each serum. The results are expressed as a 
ratio between the number of thrombi and the number of microvessels examined and as a percentage 
of occluded microvessels. The data are reported as mean + SD. (C) Sections of the ileal mesentery 
showing endovascular thrombi in anti-D1 treated rat and undetectable in the vessels of animals 
receiving anti-D4/5 positive or anti-β2GPI negative sera. Original magnification 100x. Scale bar 50 
μm. 
 
Figure 3. Deposition of β2glycoprotein I (β2GPI), human IgG and C3 on mesenteric vessels of 
rats treated with antibodies to domain 5 (D5) or domain 1 (D1) of β2GPI. The animals were 
treated with LPS followed by the injection of antibodies directed against domain 5 (D5), domain 1 
(D1), or negative for anti-β2GPI (NHS). Mesenteric tissue samples after 90 min analyzed for 
vascular deposition of β2GPI, human IgG and C3 by immunofluorescence. Original magnification 
200x. Scale bar 50 μm.  
 
Figure 4. Anti-domain 5 (D5) antibodies fail to interact with β2glycoprotein I (β2GPI) bound 
to cardiolipin. Reactivity of anti-D5 (aD5) (     ), anti-domain 1 (aD1) (     ) or anti-β2GPI negative 
(NHS) (     ) antibodies (50 μg/ml) against different concentrations of β2GPI bound to cardiolipin. 
Binding of IgG to: (A) cardiolipin alone; (B) 1 µg/ml cardiolipin-bound β2GPI; (C) 5 µg/ml 
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cardiolipin-bound β2GPI; (D) 75 µg/ml cardiolipin-bound β2GPI. The OD values are expressed as 
median and interquartile range and presented as box plots. *P < 0.05. 
 
Figure 5. Deposition of β2glycoprotein I (β2GPI) and IgG on mesenteric vessels of rats treated 
with patients’ and controls’ serum IgG prior to LPS challenge. The animals were treated with 
antibodies directed against domain 5 (D5), domain 1 (D1), or anti-β2GPI negative (NHS) (10 
mg/rat) before LPS administration (2.5 mg/kg body weight). Mesenteric tissue samples were 
analyzed for vascular deposition of β2GPI (left panel) and human IgG (central panel). Original 
magnification for immunofluorescence analysis 200x. Scale bar 50 μm.  
Thrombus formation in mesenteric vessels was monitored by intravital microscopy for 90 min and 
mesenteric tissue was collected at the end of the experiment. Thrombi formed in the vessels are 
indicated with arrows (right panel). Original magnification 100x. Scale bar 50 μm. 
 
Figure 6. Anti-domain 5 (D5) antibodies interact with β2glycoprotein I (β2GPI) in fluid phase. 
Reactivity of anti-D5 (aD5), anti-D1 (aD1), or anti-β2GPI negative (NHS) antibodies (50 μg/ml) 
against purified β2GPI directly coated on ELISA plates, measured after their incubation with (A) 50 
µg/ml, (B) 100 µg/ml and (C) 200 µg/ml of purified β2GPI (       ) or BSA (       ) in fluid phase. The 
OD values are expressed as median and interquartile range and presented as box plots. *P < 0.05; 
**P < 0.01. 
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Supplementary Methods 
 
Animal models 
An in vivo model of antibody-induced thrombus formation was established in male Wistar rats 
(270-300 g) (Envigo, S. Pietro al Natisone, Italy) and kept under standard conditions in the Animal 
House of the University of Trieste, Italy as previously reported in details.
1
 Briefly, the animals 
received an intraperitoneal injection of lipopolysaccharide (LPS) from Escherichia coli O55:B5 (2.5 
mg/kg body weight) (Sigma-Aldrich) 4 hours before general anesthesia. After infusion of 
Rhodamine 6G (Sigma-Aldrich) into the femoral vein, serum IgG (10 mg/rat) from patients and 
controls were slowly administered into the carotid artery. For some experiments the protocol was 
slightly changed and the animals received intraperitoneal injection of IgG 15 hours before general 
anesthesia followed by the injection of LPS by the same route. Clot formation and partial or 
complete occlusion of blood vessels were monitored by intravital microscopy and analyzed in at 
least 5 microvascular areas. The microvasculature was examined using a BX50WI microscope 
(Olympus, Center Valley, USA), equipped with CCD camera model SensiCam and SensiCam 
digital converter (PCO). The in vivo procedures were performed in compliance with the guidelines 
of European (86/609/EEC) and Italian (D.L.116/92) laws and were approved by the Italian Ministry 
of University and Research and the Administration of the University Animal House. This study was 
conducted in accordance with the Declaration of Helsinki. 
 
Antibody binding assays 
The interaction of IgG with phospholipid-bound β2GPI was evaluated by coating the wells of 96-
well polystyrene plates (Polysorp Immunoplate, Nalge Nunc International) with cardiolipin (50 
µg/ml) (Sigma-Aldrich) overnight at 4°C. After blocking the free binding sites with 1% ultrapure 
BSA (Sigma-Aldrich) in PBS (PBS/BSA), increasing concentrations of purified β2GPI (1,5,75 
µg/ml) were added and left to incubate for 2 hours at room temperature. Free β2GPI was removed 
by washing with the blocking buffer and phospholipid-bound β2GPI was allowed to react with IgG 
(50 µg/ml) from patients and controls for additional 2 hours at room temperature. Bound antibodies 
were detected with alkaline phosphatase-conjugated goat anti-human IgG (Sigma-Aldrich). 
The interaction of IgG with soluble β2GPI was evaluated by incubating patients’ and controls’ IgG 
(50 µg/ml) with increasing concentrations (50,100,200 µg/ml) of human purified β2GPI or BSA as 
unrelated antigen for 1 hour at 37°C followed by overnight incubation at 4°C in a tube rotator. The 
samples were centrifuged at 3,000 g for 5 min at room temperature and the residual un-complexed 
2 
 
antibodies were tested using -irradiated polystyrene plates (Combiplate EB, Labsystems) directly 
coated with purified human β2GPI (10 µg/ml) as previously described.
2
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Supplementary Table 1. Clinical and laboratory characteristics of the patients and controls 
Sample 
ID 
Age  
/sex 
Diagnosis 
aCL IgG, 
GPL
*
 
a2GPI 
IgG, OD
†
 
aD1 IgG 
AU
‡ 
aD4,5 
IgG AU
‡
 
LA AT VT PM 
 P1 35/F 
APS non-
criteria 
    0 1.45 9 59 neg No No 2EM 
P2 56/F aPL carrier   20 1.10 13 39 neg No No No 
P3 29/F 
APS non-
criteria 
    4 0.93 24 49 neg No No 2EM 
P4 36/F 
APS non-
criteria 
    3 0.98 15 63 neg No No FGR 
P5 60/M 
APS non-
criteria 
  10 0.76 6 44 neg No SVT NA 
P6 34/F PAPS   88 1.73 69 11 pos Yes No No 
P7 51/F PAPS 155 1.56 78 13 pos Yes No Yes 
P8 34/F SAPS   67 0.62 104 10 pos No Yes No 
P9 46/M PAPS 131 1.68 60 7 pos Yes Yes NA 
P10 46/F PAPS 181 1.72 66 15 pos No No Yes 
NHS1 39/F 
healthy 
ctrl 
   6 0.00 0 7 neg No No No 
NHS2 27/F 
healthy 
ctrl 
   5 0.04 4 6 neg No No No 
NHS3 43/F 
healthy 
ctrl 
   8 0.03 13 11 neg No No No 
NHS4 42/F 
healthy 
ctrl 
 10 0.00 16 18 neg No No No 
NHS5 34/F 
healthy 
ctrl 
   6 0.00 0 6 neg No No No 
aCL indicates anti-cardiolipin antibodies; a2GPI, anti-2glycoprotein I antibodies; LA, lupus anticoagulant; AT, arterial 
thrombosis; VT, venous thrombosis; PM, pregnancy morbidity, as defined by Miyakis et al
1
; EM, early miscarriages; 
FGR, fetal growth retardation; SVT, superficial venous thrombosis; PAPS, primary antiphospholipid syndrome; aPL 
carrier, antiphospholipid-positive asymptomatic subject; SAPS, secondary antiphospholipid syndrome; ctrl, control; 
D4/5, 2GPI domains 4/5; D1, 2GPI domain 1; and NA, not applicable. 
*
aCL IgG cut-off 20 GPL; 
†
 a2GPI IgG cut-off 
0.170 OD; 
‡
Anti-2GPI D4/5 cut-off 19 AU; and anti-2GPI D1 cut-off 25 AU 
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Supplementary Figure 1. Sequences of peptides obtained by trypsin degradation of 
recombinant domains 4 and 5. The amino acid sequences of domains 4 and 5 are underlined and 
included in the published sequence of β2GPI.3 
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